New trends in cholinergic therapy for Alzheimer disease: nicotinic agonists or cholinesterase inhibitors?
E Giacobini - Progress in Brain Research, 1996 - Elsevier
Publisher Summary Cholinesterase inhibitors (ChEI) are the only drugs demonstrating
clinical efficacy in the treatment of Alzheimer's disease (AD). The resulting increase in …
clinical efficacy in the treatment of Alzheimer's disease (AD). The resulting increase in …
Double-blind, placebo-controlled study of metrifonate, an acetylcholinesterase inhibitor, for Alzheimer disease
RE Becker, JA Colliver, SJ Markwell… - Alzheimer Disease & …, 1996 - journals.lww.com
Fifty patients with probable Alzheimer disease (AD) completed a 3-month double-blind study
to compare metrifonate to placebo. We dosed metrifonate to achieve a 40–60% inhibition of …
to compare metrifonate to placebo. We dosed metrifonate to achieve a 40–60% inhibition of …
The Effect of Cholinesterase Inhibitors on the Secretion of APPS from Rat Brain Cortex a
E Giacobini, F Mori, CC LAI - Annals of the New York Academy …, 1996 - Wiley Online Library
In this study we examined the question whether cholinesterase inhibitors (ChEI) could alter
the release of amyloid precursor protein (APP) from superfused brain cortical slices of the rat …
the release of amyloid precursor protein (APP) from superfused brain cortical slices of the rat …
Preclinical pharmacology of metrifonate: a promise for Alzheimer therapy
BH Schmidt, VC Hinz, A Blokland… - … : From Molecular Biology …, 1996 - Springer
Among the multiple transmitter deficits which have been described in Alzheimer's Disease
(AD), the degeneration of brain cholinergic cell bodies is the most sensitive, specific and …
(AD), the degeneration of brain cholinergic cell bodies is the most sensitive, specific and …
Phorbol Esters but Not the Cholinergic Agonists Oxotremorine‐M and Carbachol Increase Release of the Amyloid Precursor Protein in Cultured Rat Cortical Neurons
Conventional secretory processing of the amyloid precursor protein is nonamyloidogenic,
releasing carboxyl‐terminus‐truncated amyloid precursor protein derivatives while cleaving …
releasing carboxyl‐terminus‐truncated amyloid precursor protein derivatives while cleaving …
Industry Perspectives on the Marketing of Anti-Alzheimer Disease Therapy
R van der Mark - Alzheimer Disease: From Molecular Biology to …, 1996 - Springer
Most pharmaceutical companies originated in the late 18th or 19th century as chemical and
later as dye-stuff producers. The typical activities of those involved in marketing in those …
later as dye-stuff producers. The typical activities of those involved in marketing in those …